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ABstrAct
Objective Bone marrow lesions (BMLs) are well 
described in osteoarthritis (oA) using MrI and are 
associated with pain, but little is known about their 
pathological characteristics and gene expression. We 
evaluated BMLs using novel tissue analysis tools to gain 
a deeper understanding of their cellular and molecular 
expression.
Methods We recruited 98 participants, 72 with 
advanced oA requiring total knee replacement (tKr), 12 
with mild oA and 14 non-oA controls. participants were 
assessed for pain (using Western ontario and McMaster 
Universities osteoarthritis Index (WoMAC)) and with 
a knee MrI (using MoAKS). tissue was then harvested 
at tKr for BML analysis using histology and tissue 
microarray.
results the mean (Sd) WoMAC pain scores were 
significantly increased in advanced oA 59.4 (21.3) and 
mild oA 30.9 (20.3) compared with controls 0.5 (1.28) 
(p<0.0001). MoAKS showed all tKr tissue analysed 
had BMLs, and within these lesions, bone marrow 
volume was starkly reduced being replaced by dense 
fibrous connective tissue, new blood vessels, hyaline 
cartilage and fibrocartilage. Microarray comparing oA 
BML and normal bone found a significant difference in 
expression of 218 genes (p<0.05). the most upregulated 
genes included stathmin 2, thrombospondin 4, matrix 
metalloproteinase 13 and Wnt/notch/catenin/chemokine 
signalling molecules that are known to constitute 
neuronal, osteogenic and chondrogenic pathways.
conclusion our study is the first to employ detailed 
histological analysis and microarray techniques to 
investigate knee oA BMLs. BMLs demonstrated areas 
of high metabolic activity expressing pain sensitisation, 
neuronal, extracellular matrix and proinflammatory 
signalling genes that may explain their strong association 
with pain.
IntrOductIOn
Osteoarthritis (OA) is the most common form of 
arthritis worldwide affecting more than 27 million 
adults in the USA alone1 and is a major cause of 
pain and functional disability. OA prevalence is set 
to rise globally with ageing populations accompa-
nied by the rising epidemic of obesity.2 OA most 
commonly affects large weight-bearing joints, 
affecting the knees in up to 37% of adults over 
60.1 Pain is a major symptom for people with OA, 
with 16.7% of US adults aged 45 years and above 
reporting pain as a predominant problem.1
Pain in OA is thought to arise from several 
structures within the arthritic joint, including the 
synovium (from which prostaglandins, leukot-
rienes and inflammatory mediators are released), 
joint effusions, joint capsule involvement, tendon 
and muscle weakness that all contribute to pain 
and reduced function.3 Synovitis is often observed 
by MRI in OA and strongly correlates with pain.4 
Cartilage degradation is one of the hallmarks of 
OA disease5 and exposes the structures from which 
pain is most likely arising as cartilage is an avas-
cular, aneural structure composed largely of extra-
cellular matrix (ECM) embedded sparsely with 
chondrocytes. Recent interest has grown in the 
importance of bone marrow lesions (BMLs) in rela-
tion to pain in OA. Epidemiological studies have 
shown a strong correlation between BMLs observed 
by MRI and OA-related knee pain in several large 
cohorts,6 7 with an OR of 3.2 for the association of 
BMLs with pain. The data outlined above demon-
strate the multifactorial nature of OA and how pain 
mechanisms are supported by the biopsychosocial 
model of pain.
Recently, BMLs have been shown to be a very 
early biomarker of joint damage in OA6 7 with 
descriptions of their histology and histomorphom-
etry. However, no previous transcriptomic studies 
of BMLs in OA are described. In the current study, 
we describe novel findings demonstrating BMLs 
have features of angiogenesis, fibrosis, new carti-
lage formation and increased bone turnover with 
disruption of the physiological osteochondral inter-
face. Whole transcriptomic analysis of BML regions 
found upregulated expression of genes involved in 
neurogenesis, pain sensitisation, chemokine and 
cytokine signalling as well as cartilage remodelling 
pathways.
MAterIAls And MethOds
All study procedures were carried out after ethical 
approval was granted (Health Research Authority 
approval number 12/LO/1970 and clinical  trials. 
gov identifier NCT02603939). Participants 
attending the South London Elective Orthopaedic 
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Centre were recruited at assessment for total knee replacement 
(TKR), comprising the ‘advanced OA group’. For the ‘mild OA’ 
group, participants were recruited from rheumatology clinics 
at St George’s University Hospitals NHS Foundation Trust. For 
bone tissue controls, participants undergoing surgery following 
trauma, amputation or trochleoplasty were recruited (approval 
number 09/H0806/45) with no clinical or radiographic arthritis. 
Blood and urine samples were also obtained with full consent for 
biomarker studies.
study criteria
Eligibility for participation included age of 35–90 years, 
presenting with pain and fulfilling ACR criteria for the diag-
nosis of knee OA.8 Participants continued to experience pain 
despite treatment for OA.9 All participants underwent baseline 
knee radiography to confirm knee OA with a Kellgren-Lawrence 
grade of greater than 2 in the affected tibio-femoral knee joint.10
clinical data collection
All scores were collected for participants with advanced OA 
and mild OA. For controls, Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) was not collected 
as participants underwent different surgeries. The primary pain 
score was the WOMAC with subscales for pain, stiffness and 
function.11 Participants were asked to score based on symptoms 
in the last 48 hours. Data were also collected for body mass 
index (BMI), Visual Analogue Scale pain rating 0–1012 and the 
Hospital Anxiety and Depression Scale.13
Molecular methods
Total RNA was isolated from approximately 200 mg of bone 
tissue. Amplified labelled cRNA samples (600 ng) were hybri-
dised to Agilent whole human genome 60 k microarray chips. 
Array signal intensities were analysed by the Agilent Gene-
Spring GX software. Significant differentially expressed entities 
between bone samples from healthy controls and OA partici-
pants were selected using a union of a Student’s/moderated t-test 
corrected for multiple comparisons with the Bonferroni correc-
tion (p<0.05). Further methodical details are provided in the 
online supplementary methods. 14–17
stAtIstIcAl AnAlysIs
Data were anonymised for all analyses independently by the 
research team who were not involved in diagnosing or treating 
the study participants. To detect significant differences between 
groups at p<0.05, recruitment of at least 80 subjects was 
required, and we achieved n=98 participants. GraphPad Prism 
V.7 was used for all analyses, and significance was set at p<0.05 
for all analyses. For microarray statistical analysis, refer to online 
supplementary methods.
results
Demographic data showed that our participants were representa-
tive of a knee OA population. Knee OA participants who under-
went TKR had a high BMI and high pain scores measured by 
WOMAC (table 1). The mean (SD) WOMAC pain scores were 
significantly increased in advanced OA 59.4 (21.3) and mild 
table 1 Demographics showing characteristics of study population key. Data presented as means and SD.
Advanced OA Mild OA tissue control
Number* 72 12 10
Age range
Mean (SD)
51–88
69.1 (7.7)
49–79
62.2 (8.5)
21–88
56.2 (27.7)
Gender
Female N (%)
55 (76.4) 9 (75) 9 (90)
Body mass index
Mean (SD)
32.5 (5.7) 28.8 (3.9) N/A
WOMAC pain
Mean (SD)
59.4 (21.3) 30.9 (20.3) N/A
WOMAC stiffness
Mean (SD)
62.8 (25.4) 33.0 (29.7) N/A
WOMAC function
Mean (SD)
59.8 (20.6) 34.0 (24.3) N/A
NRS pain
Mean (SD)
5.7 (2.3) 2.6 (2.4) N/A
HADS
Mean (SD)
12.6 (7.2) 9.6 (6.7) N/A
MOAKS* N (%)
BML
MOAKS=0 
MOAKS=1 
MOAKS=2 
MOAKS=3
9 (14.1)
52 (81.3)
3 (4.6)
0 (0)
4 (57.1)
3 (42.9)
0 (0)
0 (0)
N/A
Synovitis/effusion
N (%)
MOAKS=0 
MOAKS=1 
MOAKS=2
MOAKS=3
2 (3.1)
28 (43.8)
18 (28.1)
16 (25)
2 (28.6)
2 (28.6)
1 (14.2)
2 (28.6)
N/A
Cartilage damage
N (%)
MOAKS=0 
MOAKS=1 
MOAKS=2
MOAKS=3
0 (0)
16 (25)
41 (64.1)
7 (10.9)
4 (57.1)
3 (42.9)
0 (0)
0 (0)
N/A
Clinical Management Underwent knee replacement surgery Medical management Underwent other surgery
BML, bone marrow lesion; HADS, Hospital Anxiety and Depression Scale; MOAKS, MRI Knee Osteoarthritis Score; NRS, Numerical Rating Scale; OA, osteoarthritis; WOMAC, 
Western Ontario and McMaster Universities Osteoarthritis Index.
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OA 30.9 (20.3) compared with controls 0.5 (1.28) (p<0.0001), 
showing the advanced OA group had significantly more severe 
pain and functional impairment.
A mixture of OA participants was identified, and they were 
classified as severe or mild based on MRI. In the advanced 
OA group, 81.3% of participants had up to 33% of the bone 
volume (MOAKS score 1) forming a BML in at least one of the 
21 measured regions, in addition to significant levels of syno-
vitis and cartilage damage (table 1). MRI scans found BML areas 
to be invariably associated with regions of established carti-
lage damage, particularly in medial tibial regions, which were 
the focus of our tissue and microarray to maintain consistency 
of anatomical tissue lesions analysed. We found that 37.5% of 
grade 1 and 2 BML were in the medial tibial compartment, with 
12.5% in the lateral tibial compartment. The remainder were 
distributed in the femur, trochlea and patella. For microarray, 
50% samples were localised in the medial tibial compartment, 
35.7% were found in the lateral tibial compartment and 14.2% 
crossed both tibial compartments.
Trends for WOMAC pain with individual MOAKS modali-
ties showed higher WOMAC pain scores were associated with 
significantly greater BMLs in the advanced OA versus mild OA 
groups (see online supplementary figure S1). There was also a 
trend of increasing WOMAC pain with worsening MOAKS-
scored synovitis, although these correlations did not reach statis-
tical significance.
Histological analysis showed most normal bone marrow was 
adipocytic with adipocytes being the primary bone lining cells 
(figure 1). The bone volume fraction was starkly reduced in 
BML areas, with marrow replaced by new blood vessels, dense 
fibrous connective tissue, hyaline cartilage and fibrocartilage. 
Areas of aggressive resorption were found at the periphery of 
BML zones alongside regions of cartilaginous aggregates found 
at least 2 mm deep to the articular surface embedded within 
the bone compartment. Regions of vascular proliferation with 
fibrocartilage were interspersed with areas of de novo cartilage 
formation. Other BML regions exhibited a cellular infiltrate 
working through the osteoid network. Histological quantifica-
tion found the BML group had increased vascular proliferation, 
cellular infiltration and trabecular thickening when compared 
with the non-BML (NBML) group (p<0.05).
Whole transcriptomic analysis identified 218 entities to be 
significantly differentially expressed between the OA BML and 
control bone samples (p<0.05) (figures 2 and 3). The most 
highly upregulated genes were stathmin 2 (STMN2), ATP-binding 
cassette protein, thrombospondin 4 (THBS4), matrix metallo-
proteinase 13 (MMP-13) and chromosome 21 open reading 
frame, which are genes involved in diverse functions including 
bone remodelling, pain sensitisation and matrix turnover (see 
Discussion). The most downregulated genes included haemo-
globin, S100 calcium binding protein A12, hemogen, proplatelet 
basic protein ((chemokine C-X-C) motif ligand 7) and delta 
amino levulinate synthase 2 (table 2 see online supplementary 
table S1 for full list).
Among other significantly upregulated genes were the 
epidermal growth factor (EGF)-like domain (EGFL6), which is 
involved in cell adhesion, apoptosis and calcium binding; collagen 
type XVI (COL16A1) with functions in ECM organisation, 
cell adhesion and integrin-mediated signalling; and G protein 
coupled receptor (GPR158), which facilitates signal transduction 
and binds hormones/neurotransmitters and ATPase H+ trans-
porting lysosomal (ATP6V0D2) gene expressed at axon termini 
and synaptic vesicles that is implicated in neuron projection. 
We also found upregulation of the DIRAS family, GTP-binding 
RAS-like 2 (DIRAS2) which is a Ras GTPase implicated in neuro-
degeneration. PC4 and SFRS1 interacting protein 1 (PSIP1) were 
also identified and are molecules involved in neuroepithelial 
stem cell differentiation, neurogenesis and apoptosis. Neuronal 
tyrosine phosphorylated phosphoinositide-3-kinase adaptor 2 
(NYAP2) was also detected, which is a gene involved in neuronal 
development, interacting with WAVE1 proteins and is implicated 
in cytoskeletal modelling. We also found catenin (cadherin-asso-
ciated protein) (CTNND2) upregulation, an adhesive junction 
associated protein implicated in bone, pain sensitisation, brain 
development and cancer formation.
Gene ontology analysis identified 166 of the 218 significantly 
differentially regulated entities to be associated with 59 canonical 
pathways. The angiogenic, Alzheimer disease-presenilin pathway, 
EGF/FGF/gonadotrophin signalling, inflammation mediated by 
chemokine and cytokine signalling with PDGF/Notch/vascular 
epidermal growth factor (VEGF) and Wnt signalling pathways 
were a few of which had the greatest number of entities related.
Quantitative polymerase chain reaction analysis confirmed 
STMN2, MMP-13 and THBS4 were significantly upregu-
lated in BML regions compared with the control comparator 
group. THBS4 and STMN2 were the most highly upregulated 
genes between the BML and control bone groups (p<0.0001), 
reflecting comparable results to the microarray (figure 4). MMP-
13 and STMN2 were upregulated within BML regions compared 
with NBML matched regions (p<0.0001). However THBS4 
was found to be most upregulated in the NBML compared with 
both BML and control groups. Serum STMN2 levels were not 
significantly increased in mild/ advanced OA groups compared 
with controls. Protein quantification of STMN2 in BML 
tissue found control bone to have higher presence of STMN2 
compared with BML bone (p<0.0001). Functional significance 
of MMP-13 protein activity, one of the highest array-expressed 
genes, found a significant increase in urine CTX-II levels, that 
is, cleavage products of type II collagen, in the advanced OA 
group compared with mild OA and control groups (p<0.001) 
(see online supplementary figure S2).
dIscussIOn
BMLs have been well described by MRI in knee OA,6 7 18 but 
very little is known about their transcriptomic expression. To our 
knowledge, our study is the first to use a multimodal approach 
with MRI to locate knee OA BMLs, followed by detailed histo-
logical analysis and whole transcriptomic techniques for a multi-
variate interrogation of the changes seen within BMLs.
Bone marrow signal changes were first described on MRI 
by Wilson et al who used the term ‘bone marrow oedema’ 
to describe MRI findings in painful joints.19 Studies so far 
have focused on acquiring data from patients undergoing joint 
surgery of the knee and hip. Zanetti et al determined histolog-
ically that BMLs contained normal fatty marrow with marrow 
necrosis, necrotic or remodelled trabeculae, oedema and bone 
marrow bleeding.20 The same group matched MRI changes to 
BML abnormalities in participants undergoing TKR and found 
regions of normal tissue alongside bone marrow fibrosis, 
oedema and bleeding. In a hip and knee OA study, Hunter et al 
reported increased bone volume fraction but decreased tissue 
mineral density within BML using light microscopy.21 Samples 
from the lesion area showed increased trabecular thickness, 
with granulation, oedema, necrosis, fibrinoid deposition and 
hyperplasia of blood vessels. Taljanovic reported one of the 
largest histological studies of hip OA BML, where regions 
of fibrosis and microfracture formation at different stages of 
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healing were observed.22 Leydet-Quilici et al also described 
oedema, necrosis and fibrosis within BML biopsies.23 Using 
MRI, Roemer et al previously demonstrated that progression 
of disease and the development of BMLs correlated with an 
increased risk of cartilage loss within the same subregion and 
that regions without BMLs are associated with decreased risk 
of cartilage loss,24 changes that our work supported. Carrino 
et al25 reported 87% of subchondral cysts were associated 
with BML abnormalities, which our analysis confirmed on 
MRI and by histology. In comparison with other studies, our 
detailed MRI matching with histological techniques allowed 
improved visualisation of BMLs, with direct observation of 
areas appearing as BML-associated cystic structures on MRI 
and transcriptomic expression. We found higher WOMAC 
pain scores with greater MOAKS-measured cartilage damage, 
as suggested by previous studies.7
Figure 1 (A) Coronal plane of MRI scan visualising BML and associated cyst. (B) Axial plane of MRI scan presenting BML and associated cyst. 
(C) Macroscopic view of tibial BML and cystic area. (D) Image of cross section cut through BML and cyst localised by MRI revealing a gelatinous 
aggregate. (E) H&E staining of cystic region presenting cellular infiltrate in marrow spaces. (F) H&E staining of subchondral cyst forming. (G) H&E 
staining of BML region with vascular proliferation and cellular infiltration. (H) H&E staining of BML visualising a chondrification centre near the 
tidemark. (I) H&E staining of adipocyte in bone compartment with a soft tissue infiltrate working through osteoid network. (J) H&E staining of BML 
showing areas of thickened trabecular adjacent to thinning trabeculae. (K) H&E staining of BML demonstrating areas of fibrotic cartilage formation 
within the subchondral bone compartment. (L) Quantification of histology analysing 50 BML FOVs and 40 non-BML (NBML) FOVs for blood vessels 
(BV), cartilage within bone compartment (Cart), cysts (Cys), myxoid/fibrous tissue (M/F), cellular infiltrate (Inf) and trabecular thickening (TT) (n=4). 
A percentage for the presence of each histological feature was determined for each group. Significance was tested between the groups using 
Friedman test (*p<0.05). (M) Magnification of each histological change within the bone compartment: BV within subchondral bone, Cart within bone 
compartment with a chondrification centre, Cys within subchondral bone, M/F adjacent to subchondral bone, Inf within the osteoid network and 
TT. BML, bone marrow lesion; FOV, field of view.
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In our study, cystic BML areas were surrounded by regions of 
fibrosis, infiltration by inflammatory cells and vascular prolifera-
tion. Previous hypotheses that BMLs could be precystic but that 
not all BMLs become cystic is also supported by our histological 
findings, where we observed cystic structures within the areas 
defined as cysts using MRI, and also adjacent to areas of fibro-
cartilage, vascular proliferation, chondrogenesis and amorphous 
tissue deposition. We observed new cartilage forming deep 
within the subchondral bone compartment. The new cartilage 
tissue within the BML could be arising from mesenchymal stem 
cells (MSCs) in the marrow, which is seen by other groups.26 
Campbell et al reported an altered phenotype of MSCs in hip 
OA BMLs, showing BML-derived MSCs undergo osteochondral 
angiogenesis and have lower proliferation and mineralisation 
capacities.27
From our microarray, the highest upregulated gene was 
STMN2, a phosphoprotein involved in regulating microtubule 
function, responsiveness to nerve growth factor (NGF), neuronal 
growth and osteogenesis.28 Upregulation of STMN2 within BML 
could lead to new neuronal structures and expansion of the 
BML in OA, thereby causing pain.29 Stathmin 2 protein expres-
sion was higher in normal than BML bone, which could reflect 
increased stathmin 2 turnover in OA BMLs.
We also identified neuronal markers including thrombos-
pondin 4 (THBS4), implicated in the inflammatory response to 
Central Nervous system (CNS) injury, presynaptic hypersensi-
tivity and neuropathic pain states.30 In animal models of pain 
sensitisation, THBS4 levels are increased locally in dorsal root 
ganglion neurons and contribute to pain behaviour, which can 
be inhibited by the calcium channel modulator gabapentin.31
Figure 2 (A) Bar chart presenting the most significantly upregulated and downregulated entities by fold change (FC). One hundred twenty-eight 
entities were found to be upregulated and 90 were downregulated. The mean WOMAC pain score in the OA microarray group was 61.4, and all 
subjects in the OA array group had a MOAKS BML score of at least 1, with cartilage and synovitis scores of at least 2. (B) Pearson’s correlation 
hierarchical clustering of 218 genes clearly segregating the OA BML group from the control group.
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Other upregulated genes involved in neuronal morpho-
genesis included ATP6V0D2, PSIP1, NYAP2, FERM and PDZ 
containing 4 (FRMPD4), implicated in CNS development and 
pain states.32 33 ECM genes were also represented in the array, 
including MMP-13 and collagens, COL16A1, fibronectins and 
growth factors, which are known to be bound within the ECM.34
Figure 3 (A) Gene ontology analysis of 218 differentially expressed entities found 166 genes associated with 59 canonical pathways. Pie chart 
of the 24 predominant pathways identified. The main significant correlation for WOMAC pain with gene correlation was for MMP-13 (p<0.05). (B) 
Network analysis was performed on the differentially expressed genes by ingenuity pathway analysis (IPA). MMP-13, matrix metalloproteinase 13; 
WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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table 2 Summary of the top differentially expressed entities between the OA BML and non-OA control groups using whole transcriptomic 
analysis
Accession no symbol entity name ↑↓ Abs Fc log Fc P Value* P Value†
nM_007029 STMN2 Stathmin 2 Up 19.30 4.27 3.67 x 10−6 1.6 x 10-6
nM_001163942 ABCB5 ATP-binding cassette, sub-family B 
(MDR/TAP), member 5
Up 12.11 3.60 2.06 x 10−6 8.86 x 10-7
nM_003248 THBS4 Thrombospondin 4 Up 11.53 3.53 1.31 x 10−4 7.35 x 10-5
nM_002427 MMP13 Matrix Metallopeptidase 13 
(collagenase 3)
Up 11.18 3.48 2.78 x 10−5 1.41 x 10-5
nr_037585 C21orf37 Chromosome 21 open reading 
frame 37
Up 9.32 3.22 3.64 x 10−6 1.65 x 10-6
nM_001167890 EGFL6 EGF-like-domain, multiple 6 Up 9.07 3.18 2.69 x 10−5 1.38 x 10-5
nM_001856 COL16A1 Collagen, type XVI, alpha 1 Up 8.25 3.04 1.8 x 10−5 9.08 x 10-6
nM_020752 GPR158 G protein-coupled receptor 158 Up 8.21 3.04 1.13 x 10−4 6.35 x 10-5
nM_012093 AK5 Adenylate kinase 5 Up 8.01 3.00 5.77 x 10−6 2.73 x 10-6
nM_174858 AK5 Adenylate kinase 5 Up 8.01 3.00 3.33 x 10−5 1.74 x 10-5
nM_152565 ATP6V0D2 ATPase, H+ transporting, lysosomal 
38kDa, V0 subunit d2
Up 7.89 2.98 4.11 x 10−6 1.91 x 10-6
ALU2 Alu 2 Element Up 7.44 2.89 1.32 x 10−6 5.82 x 10-7
nM_017594 DIRAS2 DIRAS family, GTP-binding RAS-
like 2
Up 7.14 2.84 2.8 x 10−6 1.29 x 10-6
Xr_245643 LOC101929504 Uncharacterized LOC101929504 Up 7.02 2.81 3.79 x 10−5 2.02 x 10-5
nM_021233 DNASE2B Deoxyribonuclease II beta Up 7.02 2.81 1.55 x 10−5 7.86 x 10-6
nM_014980 STXBP5L Syntaxin binding protein 5-like Up 6.72 2.75 2.68 x 10−6 1.24 x 10-6
nM_004789 LHX2 LIM homeobox 2 Up 6.71 2.75 7.61 x 10−5 4.23 x 10-5
nM_021144 PSIP1 PC4 and SFRS1 interacting protein 
1
Up 6.57 2.72 3.62 x 10−6 1.71 x 10-6
nM_020864 NYAP2 Neuronal tyrosine-phosphorylated 
phosphoinositide-3-kinase adaptor 
2
Up 6.48 2.70 2.53 x 10−5 1.33 x 10-5
nM_001332 CTNND2 Catenin (cadherin-associated 
protein), delta 2
Up 6.36 2.67 6.52 x 10−6 3.19 x 10-6
nM_032532 FNDC1 Fibronectin type III domain 
containing 1
Up 6.09 2.61 7 x 10−5 3.91 x 10-5
nM_001426 EN1 Engrailed homeobox 1 Up 5.75 2.52 1.21 x 10−6 5.56 x 10-7
nr_027054 MIR31HG MIR31 host gene (non-protein 
coding)
Up 5.64 2.50 1.21 x 10−6 1.03 x 10-4
XLOC_006820 Up 5.48 2.45 9.05 x 10−6 4.6 x 10-6
nM_014728 FRMPD4 FERM and PDZ domain containing 
4
Up 5.34 2.42 3.09 x 10−5 1.68 x 10-5
tcOns_00014487 LOC101929450 Uncharacterized LOC101929450 Up 5.33 2.41 1.31 x 10−5 6.78 x 10-6
nM_022970 FGFR2 Fibroblast growth factor receptor 2 Up 5.30 2.41 9.69 x 10−6 4.97 x 10-6
nM_012152 LPAR3 Lysophosphatidic acid receptor 3 Up 5.27 2.40 3.65 x 10−5 2 x 10-5
nM_004370 COL12A1 Collagen, type XII, alpha 1 Up 5.27 2.40 1.32 x 10−6 6.2 x 10-7
Bc043571 LOC613266 Uncharacterized LOC613266 Up 5.09 2.35 1.2 x 10−7 5.25 x 10-8
nM_000170 GLDC Glycine dehydrogenase 
(decarboxylating)
Up 5.00 2.32 6.11 x 10−5 3.46 x 10-5
nM_031913 ESYT3 Extended synaptotagmin-like 
protein 3
Up 5.00 2.32 3.61 x 10−5 1.99 x 10-5
ALU1 Alu 1 Element Down −5.02 −2.33 3.17 x 10−7 1.44 x 10-7
nM_025260 C6orf25 Chromosome 6 open reading 
frame 25
Down −5.82 −2.54 5.35 x 10−6 2.62 x 10-6
nM_080429 AQP10 Aquaporin 10 Down −6.92 −2.79 6.26 x 10-−7 2.62 x 10-6
nM_005306 FFAR2 Free fatty acid receptor 2 Down −7.29 −2.87 5.63 x 10−5 3.06 x 10−5
AB305916 TRBV28 T Cell Receptor Beta Variable 28 Down −7.50 −2.91 3.35 x 10−6 1.55 x 10−6
nM_000517 HBA2 Hemoglobin, alpha 2 Down −7.64 −2.93 7.61 x 10−7 3.25 x 10−7
XLOC_014512 Down −7.99 −3.00 2.74 x 10−7 1.1 x 10−7
nM_000517 HBA2 Hemoglobin, alpha 2 Down −8.20 −3.04 5.59 x 10−7 2.33 x 10−7
nM_016509 CLEC1B C-type lectin domain family 1, 
member B
Down −8.24 −3.04 1.03 x 10−4 2.33 x 10−7
nM_002620 PF4V1 Platelet factor 4 variant 1 Down −9.31 −3.22 2.34 x 10−6 1.04 x 10−6
Continued
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Our data demonstrate that BMLs are regions of high meta-
bolic activity with increased cell turnover, bone remodelling, 
neuronal and inflammatory gene signatures. Gene ontological 
analysis revealed canonical pathways involved in chemokine, 
integrin and cytokine signalling. We found neurodevelop-
ment and pain pathway signalling represented by the Alzhei-
mer’s, Notch, catenin, Wnt pathways alongside VEGF and 
angiogenic pathway expression. Work by Hopwood et al35 
and Chou et al36 analysing the gene expression profile of 
OA bone also found expression of bone remodelling signal-
ling pathways including Wnt, transforming growth factor and 
bone morphogenic protein and bone remodelling molecules 
such as periostin and leptin. Kusumbe et al described how 
growth of blood vessels in bone and osteogenesis are coupled, 
proposing that type H endothelial cells mediate local growth 
of the vasculature and provide specific signals for perivascular 
osteoprogenitors.37 The same group reported that endothe-
lial Notch activity promotes angiogenesis and osteogenesis 
in bone.38 We also demonstrated OMD in our BML tissue: 
Ninomiya et al showed that osteoclast activity induces OMD 
expression in bone, suggesting BMLs represent areas of active 
bone remodelling.39
The expression of both osteogenic and angiogenic genes along 
with the tissue changes we identified may suggest that vascular 
proliferation and bone formation are likely to be coupled in 
BML formation. Since blood vessels are formed within neuro-
vascular bundles, it is likely that increased neuronal pathway 
gene expression including STMN2, THBS4, PSIP1, NYAP2 and 
catenin, which were among some of the most highly expressed 
genes from our BML analysis, are implicated in neural pathway 
development, new nerve formation and pain mediation in BML 
tissue.
Accession no symbol entity name ↑↓ Abs Fc log Fc P Value* P Value†
nM_022468 MMP25 Matrix Metallopeptidase 25 Down −9.33 −3.22 4.32 x 10−5 2.28 x 10−5
nr_120522 LOC102724484 Uncharacterized LOC102724484 Down −10.04 −3.33 1.01 x 10−4 5.6 x 10−5
nM_001136503 SMIM24 Small integral membrane protein 
24
Down −10.29 −3.36 1.38 x 10−5 6.73 x 10−6
nM_030773 TUBB1 Tubulin, beta 1 class VI Down −12.37 −3.63 5.86 x 10−7 2.34 x 10−7
HSJ1167H4 Down −13.17 −3.72 3.71 x 10−6 1.65 x 10−6
nr_001552 TTTY16 Testis-specific transcript, Y-linked 
16 (non-protein coding)
Down −13.65 −3.77 6.28 x 10−5 3.34 x 10−5
nr_047499 LINC00570 Long intergenic non-protein coding 
RNA 570
Down −14.00 −3.81 1.03 x 10−4 8.67 x 10−5
nM_144673 CMTM2 CKLF-like MARVEL transmembrane 
domain containing 2
Down −14.25 −3.83 2.71 x 10−5 1.36 x 10−5
nM_001557 CXCR2 Chemokine (C-X-C motif) receptor 
2
Down −14.93 −3.90 9.27 x 10−6 4.34 x 10−6
nM_000519 HBD Hemoglobin, delta Down −15.75 −3.98 7.89 x 10−8 2.74 x 10−8
nM_002100 GYPB Glycophorin B (MNS blood group) Down −16.15 −4.01 1.03 x 10-4 1.43 x 10-4
XM_005261527 SEC14L3 SEC14-like 3 (S. cerevisiae) Down −16.65 −4.06 2.98 x 10−5 1.5 x 10−5
AK128128 FLJ46249 Down −16.90 −4.08 6.19 x 10−5 3.27 x 10−5
nM_016509 CLEC1B C-type lectin domain family 1, 
member B
Down −17.06 −4.09 1.34 x 10−5 6.39 x 10−6
nM_016509 CLEC1B C-type lectin domain family 1, 
member B
Down −17.67 −4.14 4.83 x 10−6 2.15 x 10−6
nM_002049 GATA1 GATA binding protein 1 (globin 
transcription factor 1)
Down −19.55 −4.29 7.87 x 10−5 4.21 x 10−5
nM_005764 PDZK1IP1 PDZK1 interacting protein 1 Down −20.36 −4.35 7.59 x 10-6 3.47 x 10-6
nM_006163 NFE2 Nuclear factor, erythroid 2 Down −22.54 −4.49 3.22 x 10−5 1.62 x 10−5
XLOC_013489 Down −23.69 −4.57 2.85 x 10−5 1.42 x 10−5
nM_002619 PF4 Platelet factor 4 Down −31.42 −4.97 1.26 x 10−7 4.32 x 10−8
XLOC_000346 Down −31.94 −5.00 1.26 x 10−7 2.56 x 10−5
nM_000032 ALAS2 Aminolevulinate, delta-, synthase 2 Down −33.49 −5.07 1.93 x 10-5 9.3 x 10-6
nM_005980 S100P S100 calcium binding protein P Down −33.56 −5.07 1.11 x 10-4 6.06 x 10-5
nM_005331 HBQ1 Hemoglobin, theta 1 Down −34.07 -5.09 3.58 x 10−6 1.53 x 10−6
nM_002704 PPBP Pro-platelet basic protein 
(chemokine (C-X-C motif) ligand 7)
Down −39.94 −5.32 4.11 x 10−8 1.3 x 10−8
nM_000517 HBA2 Hemoglobin, alpha 2 Down −41.07 −5.36 2.47 x 10−7 8.77 x 10−8
nM_001003938 HBM Hemoglobin, mu Down −45.11 −5.50 7.66 x 10-5 4.05 x 10−5
nM_018437 HEMGN Hemogen Down −53.12 −5.73 1.89 x 10−6 7.66 x 10−7
nM_005621 S100A12 S100 calcium binding protein A12 Down −56.95 −5.83 7.25 x 10−5 3.81 x 10−5
nM_005621 S100A12 S100 calcium binding protein A12 Down −58.82 −5.88 4.6 x 10−5 2.34 x 10−5
nM_000559 HBG1 Hemoglobin, gamma A Down −88.82 −6.47 1.94 x 10−6 7.82 x 10−7
Symbol, Entity Symbol. ↑↓, Regulation. Abs FC, Absolute Fold Change. Log FC, Log transformed Fold Change.
*Adjusted Student T-test P value for microarray corrected for multiple testing by the Bonferroni FWER method.
 †Adjusted Moderated T-test P value for microarray corrected for multiple testing by the Bonferroni FWER method
table 2 Continued 
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Our array also identified molecules within the Wnt signalling 
pathway, including catenin. Other studies have demonstrated a 
critical role for Wnt signalling in the production and persistence 
of neuropathic pain after nerve injury and bone cancer.40 Rodent 
models show that in nerve injury and bone cancer pain models, 
respectively, Wnt signalling is activated, which may contribute 
to pain by regulating pro-inflammatory cytokines interleukin-18 
and tumour necrosis factor-alpha, as well as NR2B and subse-
quent Ca2+-dependent signals in the dorsal horn. We found a 
high representation of the inflammatory chemokines and cyto-
kine signalling; other groups have also identified chemokines in 
OA pain, for example, CCR2 was recently reported to mediate 
pain in a murine model of OA.41 Our data suggest that chemo-
kine pathway molecules could be pain sensitisers in BMLs. Walsh 
et al showed that OA neurovascular changes at the osteochon-
dral junction, including vessels and both sensory and sympa-
thetic nerves breaching the tidemark, could possibly be a source 
of joint pain.42 The genes we have identified in our BML tran-
scriptome support the hypothesis of neurovascular gene upregu-
lation in BML tissue.
One of our most highly expressed genes was MMP-13, an 
enzyme expressed in cartilage, involved in regulating ECM 
turnover and cartilage destruction in OA.43 Our data showed 
that type II collagen degradation products were increased in 
urine from our advanced OA population. The de novo cartilage 
formation observed within BMLs, coupled with the increased 
transcriptomic expression of MMP-13 observed using microarray 
and the detection of MMP-13 cleavage products, could suggest 
recapitulation of the embryonic bone development phenotype 
within OA BML regions.
Limitations of our study included the sample size for 
microarray, which although on a standard format of 24 samples, 
will benefit from larger studies. Future work for protein evalu-
ation of the genes identified is needed, investigating which cells 
within BMLs are responsible for producing the genes identified 
and how BMLs develop with respect to the pathological changes 
identified in OA over time. Although we did not identify NGF, 
we found genes in neurotrophin pathways, including stathmin 2, 
which increases responsiveness to NGF,28 syntaxin, which regu-
lates brain-derived neurotrophic factor44 and pituitary adenylate 
cyclase-activation polypeptide, implicated in neuronal develop-
ment.45
In conclusion, our work demonstrates that BMLs are regions 
of high metabolic activity, with expression of genes involved 
in neuronal development, pain, ECM turnover, cartilage/bone 
formation and angiogenesis. Our findings contribute to under-
standing of OA pathogenesis and could help lead to the develop-
ment of new diagnostic tools and future therapies for this most 
common arthritic disease.
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